GSK has agreed to acquire Nuvalent (NASDAQ: NUVL) for a net cash consideration of about £7.1bn.
The lead candidates in Nuvalent’s pipeline are focused on lung cancer. Two of them have regulatory approvals pending, which, if granted, could offer significant new treatment options for certain forms of the disease.
The commitment to a 70p dividend this year has been reiterated. The company also believes it retains balance sheet headroom for further external investment.
There’s no change to GSK's 2026 guidance range of 7-9% for underlying earnings per share growth. However, if the deal closes in the third quarter, it’s expected to reduce earnings growth by low single digits, with a positive impact expected from 2029.
The shares were down in 3.4% early trading.
Our view
HL view to follow.
GSK key facts
All ratios are sourced from LSEG Datastream, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.
This article is original Hargreaves Lansdown content, published by Hargreaves Lansdown. It was correct as at the date of publication, and our views may have changed since then. Unless otherwise stated estimates, including prospective yields, are a consensus of analyst forecasts provided by LSEG. These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Investments rise and fall in value so investors could make a loss.
This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment.